Jinhe Biotechnology: Net profit expected to increase by 40%-55% in the first half of the year

Jinhe Biotechnology announced that it expects the net profit attributable to shareholders of the listed company for the first half of 2025 to be between 127 million yuan and 141 million yuan, an increase of 40%-55% compared to the same period last year. During the reporting period, the sales of the veterinary chemical drug sector continued to improve, with sales of major products, such as chlortetracycline, increasing in both domestic and overseas markets, especially with continued growth in overseas sales; the production increase after the completion of the sixth phase project ensured supply demand and created more profits. The agricultural product processing sector also contributed to the overall performance improvement due to the decline in the price of the main raw material, corn